242 related articles for article (PubMed ID: 22571614)
1. Novel targeted agents for the treatment of advanced breast cancer.
de la Vega M; Díaz-Cantón E; Alvarez RH
Future Med Chem; 2012 May; 4(7):893-914. PubMed ID: 22571614
[TBL] [Abstract][Full Text] [Related]
2. Emerging targeted therapies for breast cancer.
Alvarez RH; Valero V; Hortobagyi GN
J Clin Oncol; 2010 Jul; 28(20):3366-79. PubMed ID: 20530283
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies in breast cancer: where are we now?
Di Cosimo S; Baselga J
Eur J Cancer; 2008 Dec; 44(18):2781-90. PubMed ID: 19013786
[TBL] [Abstract][Full Text] [Related]
4. Current and emerging targeted therapies for metastatic breast cancer.
Perez EA; Spano JP
Cancer; 2012 Jun; 118(12):3014-25. PubMed ID: 22006669
[TBL] [Abstract][Full Text] [Related]
5. Targeting mitochondrial function for the treatment of breast cancer.
Deus CM; Coelho AR; Serafim TL; Oliveira PJ
Future Med Chem; 2014 Sep; 6(13):1499-513. PubMed ID: 25365234
[TBL] [Abstract][Full Text] [Related]
6. Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options.
Ocaña A; Pandiella A
Clin Cancer Res; 2008 Feb; 14(4):961-70. PubMed ID: 18281527
[TBL] [Abstract][Full Text] [Related]
7. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.
Baselga J
Oncologist; 2011; 16 Suppl 1():12-9. PubMed ID: 21278436
[TBL] [Abstract][Full Text] [Related]
8. Personalized medicine for metastatic breast cancer.
Chen TW; Bedard PL
Curr Opin Oncol; 2013 Nov; 25(6):615-24. PubMed ID: 24097103
[TBL] [Abstract][Full Text] [Related]
9. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
[TBL] [Abstract][Full Text] [Related]
10. Integration of novel targeted therapies into the systemic treatment of breast cancer--a review.
Tsakonas G; Kosmas C
J BUON; 2007; 12(3):319-27. PubMed ID: 17918284
[TBL] [Abstract][Full Text] [Related]
11. [mTOR complexes -- molecular spiders in molecular networks].
Kopper L; Tímár J
Magy Onkol; 2011 Nov; 55(4):287-94. PubMed ID: 22128312
[TBL] [Abstract][Full Text] [Related]
12. Breast Cancer: Current Molecular Therapeutic Targets and New Players.
Nagini S
Anticancer Agents Med Chem; 2017; 17(2):152-163. PubMed ID: 27137076
[TBL] [Abstract][Full Text] [Related]
13. Does the PI3K pathway play a role in basal breast cancer?
Moulder SL
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S66-71. PubMed ID: 21115424
[TBL] [Abstract][Full Text] [Related]
14. A novel single-chain variable fragment antibody against FGF-1 inhibits the growth of breast carcinoma cells by blocking the intracrine pathway of FGF-1.
Shi HL; Yang T; Deffar K; Dong CG; Liu JY; Fu CL; Zheng DX; Qin B; Wang JJ; Wang XZ; Zhu XJ
IUBMB Life; 2011 Feb; 63(2):129-37. PubMed ID: 21360642
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?
Chandarlapaty S; Modi S
J Clin Oncol; 2011 Aug; 29(23):3111-3. PubMed ID: 21730267
[No Abstract] [Full Text] [Related]
16. [Locally advanced breast cancer (methods of treatment)].
Portnoĭ SM
Vopr Onkol; 2011; 57(5):553-8. PubMed ID: 22238923
[No Abstract] [Full Text] [Related]
17. Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?
Toss A; Venturelli M; Peterle C; Piacentini F; Cascinu S; Cortesi L
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28054957
[TBL] [Abstract][Full Text] [Related]
18. [mTOR inhibitor].
Muro K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
[TBL] [Abstract][Full Text] [Related]
19. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
20. Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review).
Shigetomi H; Higashiura Y; Kajihara H; Kobayashi H
Oncol Rep; 2012 Aug; 28(2):395-408. PubMed ID: 22641286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
